Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Silicosis is a respiratory disease caused by breathing in (inhaling) silica dust. There are three types of silicosis: Simple chronic silicosis, the most common type of silicosis, results from long-term exposure (usually more than 20years) to low amounts of silica dust. Simple chronic silicosismay causepeople to have difficulty breathing. Accelerated silicosis occurs after 5 to 15 yearsof exposure of higher levels of silica.Swelling of the lungsand other symptoms occur faster in this type of silicosis than in the simple chronic form. Acute silicosis results from short-term exposure (weeks or months) of large amounts of silica.The lungs become very inflamed and can fill with fluid, causing severe shortness of breath and low blood oxygen levels. A cough, weight loss, and fatigue may also be present. Acute silicosis progresses rapidly and can be fatal within months. People who work in jobs where they are exposed to silica dust (mining, quarrying, construction, sand blasting, stone cutting) are at risk of developing this condition.
Biomarker and diagnostic research for silicosis has been reported in the published literature.
2 clinical trials registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
251 publications have been identified in PubMed for silicosis. Research spans Basic Science / Preclinical (44%), Review / Meta-Analysis (21%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 94 | 44% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC
Genetic and Rare Diseases Info Center
Research summaries |
45 |
21% |
Disease patterns and progression | 36 | 17% |
Testing and diagnosis research | 13 | 6% |
Patient case studies | 13 | 6% |
Other research | 7 | 3% |
New treatment approaches | 7 | 3% |
Clinical study results | 1 | 0% |
Ergün D (2026). [PMID: 41776796](https://pubmed.ncbi.nlm.nih.gov/41776796/). *Niger J Clin Pract*. [Basic Science / Preclinical]
Hu E (2026). [PMID: 41763510](https://pubmed.ncbi.nlm.nih.gov/41763510/). *Chem Biol Interact*. [Epidemiology / Natural History]
Leite GW (2026). [PMID: 41691440](https://pubmed.ncbi.nlm.nih.gov/41691440/). *Am J Ind Med*. [Case Report / Case Series]
Mlika M (2026). [PMID: 30726026](https://pubmed.ncbi.nlm.nih.gov/30726026/). *Unknown Journal*. [Review / Meta-Analysis]
Ban G (2026). [PMID: 41772931](https://pubmed.ncbi.nlm.nih.gov/41772931/). *Drug Deliv*. [Review / Meta-Analysis]
Rodríguez-Vega EA (2026). [PMID: 40930916](https://pubmed.ncbi.nlm.nih.gov/40930916/). *Arch Bronconeumol*. [Basic Science / Preclinical]
Lateef S (2026). [PMID: 41712445](https://pubmed.ncbi.nlm.nih.gov/41712445/). *Radiographics*. [Review / Meta-Analysis]
Wang L (2026). [PMID: 41566645](https://pubmed.ncbi.nlm.nih.gov/41566645/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Laouali AMM (2026). [PMID: 41541043](https://pubmed.ncbi.nlm.nih.gov/41541043/). *Clin Case Rep*. [Case Report / Case Series]
DeLight N (2026). [PMID: 32310362](https://pubmed.ncbi.nlm.nih.gov/32310362/). *Unknown Journal*. [Basic Science / Preclinical]